PMID- 31898798
OWN - NLM
STAT- MEDLINE
DCOM- 20210104
LR  - 20210104
IS  - 1435-4373 (Electronic)
IS  - 0934-9723 (Linking)
VI  - 39
IP  - 6
DP  - 2020 Jun
TI  - Role of linezolid combination therapy for serious infections: review of the 
      current evidence.
PG  - 1043-1052
LID - 10.1007/s10096-019-03801-x [doi]
AB  - As long-standing clinical problems, a series of complicated infections are more 
      difficult to treat due to the development of antibiotic resistance, especially 
      caused by methicillin-resistant Staphylococcus aureus (MRSA), 
      vancomycin-resistant Enterococcus faecium (VRE), and multidrug-resistant 
      Mycobacterium tuberculosis (M. tuberculosis). Moreover, the treatment options 
      available to against these infections are also becoming increasingly limited. 
      Linezolid is the first synthetic oxazolidinone antibiotic with a unique mechanism 
      of action, and its efficacy against Gram-positive bacteria has been clearly 
      demonstrated. However, the limitations of linezolid alone for the treatment of 
      these complicated infections have been reported in the recent years. Combination 
      therapy may be a good approach to enhance efficacy and prevent the development of 
      resistance. In this review, the results of multiple linezolid combination 
      therapies from in vitro, animal studies, and clinical cases for the treatment of 
      MRSA, VRE, and multidrug-resistant M. tuberculosis strains will be discussed, and 
      thus provide more relevant information for clinician in clinical practice.
FAU - Chen, Hao
AU  - Chen H
AD  - Department of Pharmacy, the First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, China.
AD  - The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of 
      Traditional Chinese Medicine, Hefei, Anhui, China.
FAU - Du, Yan
AU  - Du Y
AD  - Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical 
      University, Hefei, Anhui, China.
AD  - School of Pharmacy, Anhui Institute of Innovative Drugs, Anhui Medical 
      University, Hefei, Anhui, China.
FAU - Xia, Quan
AU  - Xia Q
AD  - Department of Pharmacy, the First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, China.
AD  - The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of 
      Traditional Chinese Medicine, Hefei, Anhui, China.
FAU - Li, Yan
AU  - Li Y
AD  - Department of Pharmacy, the First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, China.
AD  - The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of 
      Traditional Chinese Medicine, Hefei, Anhui, China.
FAU - Song, Shuai
AU  - Song S
AD  - Department of Pharmacy, the First Affiliated Hospital of Anhui Medical 
      University, Hefei, Anhui, China.
AD  - The Grade 3 Pharmaceutical Chemistry Laboratory of State Administration of 
      Traditional Chinese Medicine, Hefei, Anhui, China.
FAU - Huang, Xiaohui
AU  - Huang X
AUID- ORCID: 0000-0002-4768-9103
AD  - Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical 
      University, Hefei, Anhui, China. math2088@163.com.
AD  - School of Pharmacy, Anhui Institute of Innovative Drugs, Anhui Medical 
      University, Hefei, Anhui, China. math2088@163.com.
LA  - eng
GR  - 81173133/National Natural Science Fund of China/
PT  - Journal Article
PT  - Review
DEP - 20200102
PL  - Germany
TA  - Eur J Clin Microbiol Infect Dis
JT  - European journal of clinical microbiology & infectious diseases : official 
      publication of the European Society of Clinical Microbiology
JID - 8804297
RN  - 0 (Anti-Bacterial Agents)
RN  - ISQ9I6J12J (Linezolid)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Bacteria/drug effects/isolation & purification
MH  - Bacterial Infections/*drug therapy/microbiology
MH  - Drug Resistance, Bacterial/drug effects
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Linezolid/*therapeutic use
OTO - NOTNLM
OT  - Combination
OT  - Linezolid
OT  - Methicillin-resistant Staphylococcus aureus (MRSA)
OT  - Multidrug-resistant Mycobacterium tuberculosis (M. tuberculosis)
OT  - Vancomycin-resistant Enterococcus faecium (VRE)
EDAT- 2020/01/04 06:00
MHDA- 2021/01/05 06:00
CRDT- 2020/01/04 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2019/12/17 00:00 [accepted]
PHST- 2020/01/04 06:00 [pubmed]
PHST- 2021/01/05 06:00 [medline]
PHST- 2020/01/04 06:00 [entrez]
AID - 10.1007/s10096-019-03801-x [pii]
AID - 10.1007/s10096-019-03801-x [doi]
PST - ppublish
SO  - Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1043-1052. doi: 
      10.1007/s10096-019-03801-x. Epub 2020 Jan 2.